Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries

We are analyzing https://link.springer.com/article/10.1007/s11910-003-0031-z.

Title:
Neuroprotective agents for the treatment of acute ischemic stroke | Current Neurology and Neuroscience Reports
Description:
Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Education
  • Graphic Design
  • Science

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,016 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

We find it hard to spot revenue streams.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {๐Ÿ”}

stroke, google, scholar, pubmed, cas, acute, article, ischemic, neuroprotective, trial, study, treatment, trials, neuroprotection, patients, hypothermia, therapy, clinical, investigators, neurology, kidwell, saver, human, starkman, efficacy, focal, results, randomized, international, therapies, injury, ischemia, drugs, cerebral, cerebrovasc, dis, antagonist, privacy, cookies, content, research, agents, cardiac, arrest, design, brain, clark, grotta, med, ischaemic,

Topics {โœ’๏ธ}

n-methyl-d-aspartate antagonist dextrorphan n-methyl-d-aspartate neurotoxicity neural stem cells month download article/chapter combination tissue-plasminogen activator omega-agatoxin ivasensitive ca sidney starkman mdย &ย jeffrey randomized clinical trial full article pdf clinical trial evaluation privacy choices/manage cookies placebo-controlled trial randomized controlled trial article current neurology neuroscience reports aims randomized controlled trials clinical trial design dextrorphan study group neurodegenerative disorders randomised controlled trial subacute human stroke including trial testing nmda antagonists related subjects case-control study ischemic brain injury focal cerebral ischemia cerebral gabaergic activity article ovbiagele ischemic stroke trial cardiac arrest due acute stroke treatments 3-hour fibrinolytic therapy ischemic cell death ischemic neuronal death transient focal ischemia acute ischemic stroke acute ischemic stroke focal ischemic stroke mild therapeutic hypothermia european economic area rapidly expanding array rectify past defects restorative drug development altering body temperature agonist sun n4057 transdermal glyceryl trinitrate de haan rj reducing apoptotic death synthetic pyrimidine compound

Questions {โ“}

  • De Keyser J, Sulter G, Luiten PG: Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
  • DeGraba TJ, Pettigrew LC: Why do neuroprotective drugs work in animals but not humans?
  • Gorelick PB: Neuroprotection in acute ischemic stroke: a tale of for whom the bell tolls?
  • Grotta J: Why do all drugs work in animals but none in stroke patients?
  • Heiss W, Thiel A, Grond M, Graf R: Which targets are relevant for therapy of acute ischemic stroke?
  • Samsa GP, Matchar DB: Have randomized controlled trials of neuroprotective drugs been underpowered?
  • Warach S, Hartnett K: Dose dependent reduction in infarct growth with citicholine treatment: evidence of neuroprotection in human stroke?

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:Neuroprotective agents for the treatment of acute ischemic stroke
         description:Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
         datePublished:
         dateModified:
         pageStart:9
         pageEnd:20
         sameAs:https://doi.org/10.1007/s11910-003-0031-z
         keywords:
            Acute Stroke
            Acute Ischemic Stroke
            Piracetam
            NMDA Antagonist
            Human Clinical Trial
            Neurology
            Neurosciences
         image:
         isPartOf:
            name:Current Neurology and Neuroscience Reports
            issn:
               1534-6293
               1528-4042
            volumeNumber:3
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Current Medicine Group
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Bruce Ovbiagele
               affiliation:
                     name:University of California at Los Angeles
                     address:
                        name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chelsea S. Kidwell
               affiliation:
                     name:University of California at Los Angeles
                     address:
                        name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sidney Starkman
               affiliation:
                     name:University of California at Los Angeles
                     address:
                        name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jeffrey L. Saver
               affiliation:
                     name:University of California at Los Angeles
                     address:
                        name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Neuroprotective agents for the treatment of acute ischemic stroke
      description:Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
      datePublished:
      dateModified:
      pageStart:9
      pageEnd:20
      sameAs:https://doi.org/10.1007/s11910-003-0031-z
      keywords:
         Acute Stroke
         Acute Ischemic Stroke
         Piracetam
         NMDA Antagonist
         Human Clinical Trial
         Neurology
         Neurosciences
      image:
      isPartOf:
         name:Current Neurology and Neuroscience Reports
         issn:
            1534-6293
            1528-4042
         volumeNumber:3
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Current Medicine Group
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Bruce Ovbiagele
            affiliation:
                  name:University of California at Los Angeles
                  address:
                     name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chelsea S. Kidwell
            affiliation:
                  name:University of California at Los Angeles
                  address:
                     name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sidney Starkman
            affiliation:
                  name:University of California at Los Angeles
                  address:
                     name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jeffrey L. Saver
            affiliation:
                  name:University of California at Los Angeles
                  address:
                     name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Neurology and Neuroscience Reports
      issn:
         1534-6293
         1528-4042
      volumeNumber:3
Organization:
      name:Current Medicine Group
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of California at Los Angeles
      address:
         name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:University of California at Los Angeles
      address:
         name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:University of California at Los Angeles
      address:
         name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
         type:PostalAddress
      name:University of California at Los Angeles
      address:
         name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Bruce Ovbiagele
      affiliation:
            name:University of California at Los Angeles
            address:
               name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Chelsea S. Kidwell
      affiliation:
            name:University of California at Los Angeles
            address:
               name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Sidney Starkman
      affiliation:
            name:University of California at Los Angeles
            address:
               name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Jeffrey L. Saver
      affiliation:
            name:University of California at Los Angeles
            address:
               name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
      name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
      name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
      name:Stroke Center and Department of Neurology, University of California at Los Angeles, Los Angeles, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {๐Ÿ”—}(183)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js

5.17s.